[NCI CIRB] EA8143 (PROSPER): A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy
The purpose of this study is to compare recurrence-free survival (RFS) between patients with locally advanced renal cell carcinoma randomly assigned to perioperative nivolumab in conjunction with radical or partial
nephrectomy with patients randomized to surgery alone.
advanced renal cell carcinoma
Eligibility criteria highlighted below:
1- Diagnosis of renal mass per protocol section 3.1.1
A complete list of the eligibility criteria can be found in section 3.0 of the protocol.
18 - 110
Healthy Volunteers Needed
Duration of Participation
10 years from the time of study entry.
Knight Information Line - firstname.lastname@example.org or 503-494-1080
ECOG - ACRIN